Attorney Docket No. 066683/0190

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of Tomoki TODO et al.

Serial No. 09/679,147

Filed: October 5, 2000

USE OF SOLUBLE COSTIMULA

IMMUNO-GENE THERAPY

Group Art Unit: 1614

Examiner: Unassigned

OR FOR TUMOR

INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR §1.56 and 37 CFR §1.97

Commissioner for Patents Washington, D.C. 20231

Sir:

For:

Submitted herewith on a modified Form PTO-1449 is a listing of documents known to applicant in order to comply with applicants' duty of disclosure pursuant to 37 CFR 1.56. A copy of each listed document is being submitted to comply with the provisions of 37 CFR §§1.97 and 1.98.

The submission of any document herewith is not intended as an admission that such document constitutes prior art against the claims of the present application or that such document is considered material to patentability as defined in 37 CFR §1.56(b). Applicants do not waive any rights to take any action which would be appropriate to antedate or otherwise remove as a competent reference any document which is determined to be a prima facie prior art reference against the claims of the present application.

TIMING OF THE DISCLOSURE

The instant Information Disclosure Statement is believed to be filed in accordance with 37 CFR §1.97(b), before the mailing date of a first Office Action on the merits.

Applicant respectfully requests that the listed documents be considered by the Examiner and be made of record in the present application and that an initialed copy of Form PTO-1449 be returned in accordance with MPEP §609.

Respectfully submitted,

12 1 larch 2001

Date

Stephen A. Bent

Registration No. 29,768

FOLEY & LARDNER 3000 K Street, N.W., Suite 500

Washington, D.C. 20007-5109

Telephone: 202-672-5404 Facsimile: 202-672-5399

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of Tomoki TODO et al.

Serial No. 09/679,147

Group Art Unit: 1614

Filed: October 5, 2000

Examiner: Unassigned

For:

USE OF SOLUBLE COSTIMULATORY FACTOR FOR TUMOR

IMMUNO-GENE THERAPY

INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR §1.56 AND §1.97

Commissioner for Patents Washington, D.C. 20231

Sir:

Submitted herewith on Form PTO-1449 is a listing of documents known to applicants in order to comply with Applicants' duty of disclosure pursuant to 37 CFR 1.56. A copy of each listed document is being submitted to comply with the provisions of 37 CFR 1.97 and 1.98.

The submission of any document herewith, which is not a statutory bar, is not intended as an admission that such document constitutes prior art against the claims of the present application or that such document is considered material to patentability as defined in 37 CFR §1.56(b). Applicants do not waive any rights to take any action which would be appropriate to antedate or otherwise remove as a competent reference any document which is determined to be a *prima facie* prior art reference against the claims of the present application.

CONCISE EXPLANATION OF RELEVANCE OF EACH DOCUMENT

The foregoing documents came to Applicants' attention during a search of the corresponding PCT application. A copy of the PCT search report is attached.

TIMING OF THE DISCLOSURE

This information disclosure statement is being filed prior to the mailing of a first office action on the merits under 37 CFR §1.97(b)(3). Applicants also make the following certification.

CERTIFICATION

The undersigned hereby certifies in accordance with 37 CFR 1.97(e)(1) that each item of information contained in the information disclosure statement was cited in the PCT Search Report not more than three months prior to the filing of the statement.

Applicants respectfully request that the listed document be considered by the Examiner and formally be made of record in the present application and that an initialled copy of Form PTO-1449 be returned in accordance with MPEP §609.

Date

Respectfully submitted,

Stephen A. Bent

Attorney for Applicant Registration No. 29,768

FOLEY & LARDNER
Washington Harbour

3000 K Street, N.W., Suite 500

Washington, DC 20007-5109 Telephone: (202) 672-5404

Facsimile: (202) 672-5399